1xbet.com Bristol-Myers K.K.
1xbet.com Pharmaceutical Co., Ltd.

Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. announced 1xbet.com results of Japanese subset analysis in a Phase III DASISION study on 1xbet.com efficacy of SPRYCEL compared with imatinib for 1xbet.com treatment of patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). In this analysis, 1xbet.com primary endpoint was 1xbet.com confirmed Complete Cytogenetic Response (CCyR^*) rate by 12 months. In 1xbet.com Japanese subset analysis, confirmed CCyR was 96% for 1xbet.com SPRYCEL group (26 cases) and 70% for 1xbet.com imatinib control group (23 cases), showing high efficacy of SPRYCEL in 1xbet.com Japanese subset. As for safety profiles, it was concluded that both groups showed good tolerability. 1xbet.com results of this analysis were presented at 1xbet.com 52^ndAnnual Meeting of 1xbet.com American Society of Hematology, held in Orlando, Florida.

• *Complete cytogenetic response (CCyR) is defined as 1xbet.com state where bone marrow cell genetic evaluation finds no Philadelphia chromosome positive cells undergoing mitosis.